Celgene expands partnership with Agios into immuno-oncology

Agios lands $200 million upfront, with the potential for much more in clinical and regulatory milestones. 

By Nicole Gray • May 18, 2016

Editas forges $5 million CRISPR research deal with Cystic Fibrosis Foundation

While Editas has no approved drugs yet, the promise and hope surrounding gene-editing has spurred several development deals. 

By Nicole Gray • May 17, 2016

With generics deal pending, Teva's Europe portfolio attracts buyers

Novartis and Mylan are both reportedly interested in acquiring Teva's businesses in the U.K., Ireland, and Iceland.

By Ned Pagliarulo • May 16, 2016

Pfizer adds eczema drug in $5.2 billion deal for Anacor

Anacor's main drug candidate, crisaborole, is currently under FDA review for treatment of eczema. 

By Ned Pagliarulo • May 16, 2016

Baxter reportedly top suitor for Indian injectables maker

But the Chinese conglomerate Fosun Group has also made an offer, according to The Economic Times. 

By Ned Pagliarulo • May 12, 2016

Daiichi snaps up Japanese rights to CVD stem-cell therapy

U.K.-based Cell Therapy will receive £12.5 million upfront from the Japanese company for its Heartcel product. 

By Nicole Gray • May 11, 2016

Pfizer planning first triple-drug immuno-oncology study

Expected to begin sometime next year, the early-stage trial will combine the checkpoint inhibitor avelumab with two other drugs. 

By Nicole Gray • May 11, 2016

Medicines Co. sells off cardiovascular drugs to Italy's Chiesi

The deal could be worth up to $792 million if all milestones are hit. 

By Ned Pagliarulo • May 9, 2016

Lower sales of generic drugs weigh on Teva's first-quarter revenue

Still pending is a $40 billion acquisition of Allergan's generics business, which the Israel-based drugmaker expects to close in June. 

By Ned Pagliarulo • May 9, 2016

As Big Pharma circles, Medivation makes case for independence

Sanofi has threatened to take its $9.3 billion takeover directly to shareholders if Medivation continues to rebuff negotiations. 

By Ned Pagliarulo • May 6, 2016

Pfizer bets on Wave with drug development deal

The partnership could be worth up to $911 million if all milestones are hit.

By Nicole Gray • May 6, 2016

AMRI cuts $358M deal for Euticals

The deal will give AMRI a significant API portfolio in Europe.

By Randy Lilleston • May 5, 2016

Report: Pfizer considering takeover offer for sought-after Medivation

Medivation's board last week rejected a $9.3 billion bid from Sanofi, calling it a "substantially inadequate proposal." 

By Ned Pagliarulo • May 4, 2016

IMS, Quintiles to merge in $9B deal

The all-stock deal unites two major providers of pharma support services.

By Randy Lilleston • May 3, 2016

Medivation rejects $9.3 billion purchase bid from Sanofi

The all-cash offer was turned down unanimously by Medivation's board.

By Randy Lilleston • April 29, 2016

UBS venture fund raises $471 million for early-stage cancer investments

One of the goals of the fund will be to help bridge the gap between initial drug development and later investments by large pharma.

By Nicole Gray • April 28, 2016

AbbVie buys Stemcentrx for $5.8 billion, builds cancer drug offerings

The cash-and-stock deal gives AbbVie access to Rova-T, a small cell lung cancer treatment that has shown strong early promise.

By Randy Lilleston • April 28, 2016

Sanofi pressures Medivation to take $9.3 billion bid

After the April 15 offer drew no interest, Sanofi CEO Olivier Brandicourt makes public a letter asking Medivation CEO David Hung to explain the silence.

By Ned Pagliarulo • April 28, 2016

AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million

The gout drug just won approval from the FDA in December 2015. 

By Nicole Gray • April 26, 2016

Novartis may divest $14B stake in Roche, could generate M&A funding

The company's new heart failure drug Entresto has disappointed post-launch in the U.S., putting pressure on the Swiss drugmaker. 

By Nicole Gray • April 26, 2016

With CEO Papa headed to Valeant, Perrigo faces new challenges

The Irish drugmaker scaled back earnings expectations for 2016, citing increased competition and pricing pressures. 

By Nicole Gray • April 26, 2016

Actelion denies reports of takeover

The Swiss company also reported strong growth for its new PAH drugs in the first quarter. 

By Nicole Gray • April 22, 2016

Adding to cosmetic portfolio, Allergan buys Topokine for $85 million

This is the second deal struck by the Irish company following the collapse of its mega-merger with Pfizer. 

By Ned Pagliarulo • April 22, 2016

Boosting pipeline, AbbVie inks two deals for preclinical cancer drugs

The deals, with ArgenX and CytomX, give AbbVie a foothold in immuno-oncology. 

By Nicole Gray • April 22, 2016

In $205 million deal, Recipharm buys Kemwell's US, India CDMO businesses

The Swedish contract development firm aims to gain a foothold in the US market.

By Nicole Gray • April 21, 2016